What are you looking for?

Need help finding what you are looking for? Contact Us

Compare

Free Samples

Home Market Research Reports Pharmaceutical

PUBLISHER: Grand View Research | PRODUCT CODE: 1529764

PUBLISHER: Grand View Research | PRODUCT CODE: 1529764

Connective Tissue Disease Market Size, Share & Trends Analysis Report By Disease (Rheumatoid Arthritis), By Drug (Pharmaceuticals), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030

PUBLISHED: July 15, 2024

PAGES: 150 Pages

DELIVERY TIME: 2-10 business days

ADD TO COMPARE

SELECT AN OPTION

The global connective tissue disease market size was estimated at USD 24.04 billion in 2023 and is expected to grow at a CAGR of 6.1% from 2024 to 2030. This growth is attributed to the increasing prevalence of these diseases, advancements in diagnostic techniques & treatment approaches, and growing demand for effective treatments. The rising incidence of autoimmune and rheumatic disorders, such as rheumatoid arthritis, systemic lupus erythematosus, and scleroderma, is a significant driver for the growth of the connective tissue disease (CTD) market. According to the Lupus Foundation of America,about 1.5 million Americans and more than five million people globally are affected by some type of lupus.

Moreover, the aging population worldwide is another significant driver for the growth of the market. As individuals age, they are more prone to developing autoimmune disorders such as rheumatoid arthritis and scleroderma, both of which fall under the category of connective tissue disease. This demographic trend fuels the demand for innovative therapies and personalized medicine approaches tailored to address the specific needs of elderly patients with connective tissue diseases. Pharmaceutical companies invest in research and development activities to introduce novel treatments targeting these conditions.

Furthermore, technological advancements in precision medicine and biomarker discovery are revolutionizing the diagnosis and treatment landscape for connective tissue diseases. The emergence of targeted therapies that aim to modulate specific pathways involved in autoimmune responses is propelling market growth. For instance, biologics such as monoclonal antibodies are being developed to target key molecules implicated in CTD pathogenesis, offering patients more effective and safer treatment options. These innovations are reshaping the market by providing personalized solutions that improve patient outcomes and quality of life.

Global Connective Tissue Disease Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global connective tissue disease market report on the basis of disease, drug, distribution channel, region:

Connective Tissue Disease Outlook (Revenue, USD Million, 2018 - 2030)
Rheumatoid Arthritis (RA)
Systemic Lupus Erythematosus (SLE)
Scleroderma
Polymyositis
Dermatomyositis
Sjogren's Syndrome
Mixed Connective Tissue Disease (MCTD)
Undifferentiated Connective Tissue Disease (UCTD)
Other connective tissue disease
Connective Tissue Disease Drug Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceuticals

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Corticosteroids

Other Pharmaceuticals

Biopharmaceuticals

Biologics

TNF Inhibitors

IL-6 Inhibitors

B-cell Inhibitors

T-cell Inhibitors

Other Biologics

Biosimilars

Connective Tissue Disease Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America

U.S.

Canada

Mexico

Europe

Germany

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

Latin America

Brazil

Argentina

Middle East and Africa

South Africa

Saudi Arabia

UAE

Kuwait

Product Code: GVR-4-68040-348-8

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Disease
- 1.2.2. Drug
- 1.2.3. Distribution Channel
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
  - 1.4.5.1. Data for primary interviews in North America
  - 1.4.5.2. Data for primary interviews in Europe
  - 1.4.5.3. Data for primary interviews in Asia Pacific
  - 1.4.5.4. Data for primary interviews in Latin America
  - 1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Disease outlook
- 2.2.2. Drug outlook
- 2.2.3. Distribution Channel outlook
- 2.2.4. Regional outlook
2.3. Competitive Insights

Chapter 3. Connective Tissue Disease Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market driver analysis
  - 3.2.1.1. Increasing prevalence of connective tissue diseases
  - 3.2.1.2. Aging Population
  - 3.2.1.3. Technological advancements
- 3.2.2. Market restraint analysis
  - 3.2.2.1. High treatment cost
3.3. Connective Tissue Disease Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Technological landscape
  - 3.3.2.3. Economic landscape
- 3.3.3. Pipeline Analysis

Chapter 4. Connective Tissue Disease Market: Disease Estimates & Trend Analysis

4.1. Global Connective Tissue Disease Market: Disease Dashboard
4.2. Global Connective Tissue Disease Market: Disease Analysis
4.3. Global Connective Tissue Disease Market by Disease, Revenue
4.4. Rheumatoid Arthritis (RA)
- 4.4.1. Rheumatoid Arthritis (RA) market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Systemic Lupus Erythematosus (SLE)
- 4.5.1. Systemic Lupus Erythematosus (SLE) market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Scleroderma
- 4.6.1. Scleroderma market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Polymyositis
- 4.7.1. Polymyositis market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Dermatomyositis
- 4.8.1. Dermatomyositis market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Sjogren's Syndrome
- 4.9.1. Postpartum psychosis market estimates and forecasts 2018 to 2030 (USD Million)
4.10. Mixed Connective Tissue Disease (MCTD)
- 4.10.1. Mixed Connective Tissue Disease (MCTD) market estimates and forecasts 2018 to 2030 (USD Million)
4.11. Undifferentiated Connective Tissue Disease (UCTD)
- 4.11.1. Undifferentiated Connective Tissue Disease (UCTD) market estimates and forecasts 2018 to 2030 (USD Million)
4.12. Other connective tissue disease
- 4.12.1. Other connective tissue disease market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Connective Tissue Disease Market: Drug Estimates & Trend Analysis

5.1. Global Connective Tissue Disease Market: Drug Dashboard
5.2. Global Connective Tissue Disease Market: Drug Movement Analysis
5.3. Global Connective Tissue Disease Market Estimates and Forecasts, By Drug, Revenue (USD Million)
5.4. Pharmaceuticals
- 5.4.1. Pharmaceuticals market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.2. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
  - 5.4.2.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.3. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
  - 5.4.3.1. Disease-Modifying Anti-Rheumatic Drugs (DMARDs) market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.4. Corticosteroids
  - 5.4.4.1. Corticosteroids market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.5. Other Pharmaceuticals
  - 5.4.5.1. Other Pharmaceuticals market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Biopharmaceuticals
- 5.5.1. Biopharmaceuticals market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5.2. Biologics
  - 5.5.2.1. Biologics market estimates and forecasts 2018 to 2030 (USD Million)
  - 5.5.2.2. TNF Inhibitors

5.5.2.2.1.1. TNF Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

5.5.2.3. IL-6 Inhibitors

5.5.2.3.1.1. IL-6 Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

5.5.2.4. B-cell Inhibitors

5.5.2.4.1.1. B-cell Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

5.5.2.5. T-cell inhibitors

5.5.2.5.1.1. T-cell Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

5.5.2.6. Other Biologics

5.5.2.6.1.1. Other Biologics market estimates and forecasts 2018 to 2030 (USD Million)

5.6. Biosimilars
- 5.6.1. Biosimilars market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Connective Tissue Disease Market: Distribution Channel Estimates & Trend Analysis

6.1. Global Connective Tissue Disease Market: Distribution Channel Dashboard
6.2. Global Connective Tissue Disease Market: Distribution Channel Movement Analysis
6.3. Global Connective Tissue Disease Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
6.4. Hospital Pharmacies
- 6.4.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Retail Pharmacies
- 6.5.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Online Pharmacies
- 6.6.1. Online Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Connective Tissue Disease Market: Regional Estimates & Trend Analysis by Disease, Drug, and Distribution Channel

7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
- 7.3.1. U.S.
  - 7.3.1.1. Key country dynamics
  - 7.3.1.2. Regulatory framework/ reimbursement structure
  - 7.3.1.3. Competitive scenario
  - 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 7.3.2. Canada
  - 7.3.2.1. Key country dynamics
  - 7.3.2.2. Regulatory framework/ reimbursement structure
  - 7.3.2.3. Competitive scenario
  - 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 7.3.3. Mexico
  - 7.3.3.1. Key country dynamics
  - 7.3.3.2. Regulatory framework/ reimbursement structure
  - 7.3.3.3. Competitive scenario
  - 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
- 7.4.1. UK
  - 7.4.1.1. Key country dynamics
  - 7.4.1.2. Regulatory framework/ reimbursement structure
  - 7.4.1.3. Competitive scenario
  - 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.2. Germany
  - 7.4.2.1. Key country dynamics
  - 7.4.2.2. Regulatory framework/ reimbursement structure
  - 7.4.2.3. Competitive scenario
  - 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.3. France
  - 7.4.3.1. Key country dynamics
  - 7.4.3.2. Regulatory framework/ reimbursement structure
  - 7.4.3.3. Competitive scenario
  - 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.4. Italy
  - 7.4.4.1. Key country dynamics
  - 7.4.4.2. Regulatory framework/ reimbursement structure
  - 7.4.4.3. Competitive scenario
  - 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.5. Spain
  - 7.4.5.1. Key country dynamics
  - 7.4.5.2. Regulatory framework/ reimbursement structure
  - 7.4.5.3. Competitive scenario
  - 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.6. Norway
  - 7.4.6.1. Key country dynamics
  - 7.4.6.2. Regulatory framework/ reimbursement structure
  - 7.4.6.3. Competitive scenario
  - 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.7. Sweden
  - 7.4.7.1. Key country dynamics
  - 7.4.7.2. Regulatory framework/ reimbursement structure
  - 7.4.7.3. Competitive scenario
  - 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.8. Denmark
  - 7.4.8.1. Key country dynamics
  - 7.4.8.2. Regulatory framework/ reimbursement structure
  - 7.4.8.3. Competitive scenario
  - 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
- 7.5.1. Japan
  - 7.5.1.1. Key country dynamics
  - 7.5.1.2. Regulatory framework/ reimbursement structure
  - 7.5.1.3. Competitive scenario
  - 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.2. China
  - 7.5.2.1. Key country dynamics
  - 7.5.2.2. Regulatory framework/ reimbursement structure
  - 7.5.2.3. Competitive scenario
  - 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.3. India
  - 7.5.3.1. Key country dynamics
  - 7.5.3.2. Regulatory framework/ reimbursement structure
  - 7.5.3.3. Competitive scenario
  - 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.4. Australia
  - 7.5.4.1. Key country dynamics
  - 7.5.4.2. Regulatory framework/ reimbursement structure
  - 7.5.4.3. Competitive scenario
  - 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.5. South Korea
  - 7.5.5.1. Key country dynamics
  - 7.5.5.2. Regulatory framework/ reimbursement structure
  - 7.5.5.3. Competitive scenario
  - 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.6. Thailand
  - 7.5.6.1. Key country dynamics
  - 7.5.6.2. Regulatory framework/ reimbursement structure
  - 7.5.6.3. Competitive scenario
  - 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
- 7.6.1. Brazil
  - 7.6.1.1. Key country dynamics
  - 7.6.1.2. Regulatory framework/ reimbursement structure
  - 7.6.1.3. Competitive scenario
  - 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.2. Argentina
  - 7.6.2.1. Key country dynamics
  - 7.6.2.2. Regulatory framework/ reimbursement structure
  - 7.6.2.3. Competitive scenario
  - 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
- 7.7.1. South Africa
  - 7.7.1.1. Key country dynamics
  - 7.7.1.2. Regulatory framework/ reimbursement structure
  - 7.7.1.3. Competitive scenario
  - 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.2. Saudi Arabia
  - 7.7.2.1. Key country dynamics
  - 7.7.2.2. Regulatory framework/ reimbursement structure
  - 7.7.2.3. Competitive scenario
  - 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.3. UAE
  - 7.7.3.1. Key country dynamics
  - 7.7.3.2. Regulatory framework/ reimbursement structure
  - 7.7.3.3. Competitive scenario
  - 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.4. Kuwait
  - 7.7.4.1. Key country dynamics
  - 7.7.4.2. Regulatory framework/ reimbursement structure
  - 7.7.4.3. Competitive scenario
  - 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Company/Competition Categorization
8.2. Vendor Landscape
- 8.2.1. List of key distributors and channel partners
- 8.2.2. Key customers
- 8.2.3. Key company market share analysis, 2023
- 8.2.4. AbbVie, Inc.
  - 8.2.4.1. Company overview
  - 8.2.4.2. Financial performance
  - 8.2.4.3. Product benchmarking
  - 8.2.4.4. Strategic initiatives
- 8.2.5. Amgen, Inc.
  - 8.2.5.1. Company overview
  - 8.2.5.2. Financial performance
  - 8.2.5.3. Product benchmarking
  - 8.2.5.4. Strategic initiatives
- 8.2.6. Boehringer Ingelheim International GmbH
  - 8.2.6.1. Company overview
  - 8.2.6.2. Financial performance
  - 8.2.6.3. Product benchmarking
  - 8.2.6.4. Strategic initiatives
- 8.2.7. Bristol-Myers Squibb Company
  - 8.2.7.1. Company overview
  - 8.2.7.2. Financial performance
  - 8.2.7.3. Product benchmarking
  - 8.2.7.4. Strategic initiatives
- 8.2.8. F. Hoffmann-La Roche Ltd.
  - 8.2.8.1. Company overview
  - 8.2.8.2. Financial performance
  - 8.2.8.3. Product benchmarking
  - 8.2.8.4. Strategic initiatives
- 8.2.9. Johnson & Johnson Services, Inc.
  - 8.2.9.1. Company overview
  - 8.2.9.2. Financial performance
  - 8.2.9.3. Product benchmarking
  - 8.2.9.4. Strategic initiatives
- 8.2.10. Lily
  - 8.2.10.1. Company overview
  - 8.2.10.2. Financial performance
  - 8.2.10.3. Product benchmarking
  - 8.2.10.4. Strategic initiatives
- 8.2.11. Novartis AG
  - 8.2.11.1. Company overview
  - 8.2.11.2. Financial performance
  - 8.2.11.3. Product benchmarking
  - 8.2.11.4. Strategic initiatives
- 8.2.12. Pfizer Inc.
  - 8.2.12.1. Company overview
  - 8.2.12.2. Financial performance
  - 8.2.12.3. Product benchmarking
  - 8.2.12.4. Strategic initiatives
- 8.2.13. Regeneron Pharmaceuticals Inc.
  - 8.2.13.1. Company overview
  - 8.2.13.2. Financial performance
  - 8.2.13.3. Product benchmarking
  - 8.2.13.4. Strategic initiatives
- 8.2.14. UCB S.A.
  - 8.2.14.1. Company overview
  - 8.2.14.2. Financial performance
  - 8.2.14.3. Product benchmarking
  - 8.2.14.4. Strategic initiatives

Product Code: GVR-4-68040-348-8

List of Tables

Table 1 List of abbreviation
Table 2 North America Connective Tissue Disease market, by region, 2018 - 2030 (USD Million)
Table 3 North America Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 4 North America Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 5 North America Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 6 U.S. Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 7 U.S. Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 8 U.S. Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 9 Canada Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 10 Canada Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 11 Canada Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 12 Mexico Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 13 Mexico Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 14 Mexico Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 15 Europe Connective Tissue Disease market, by region, 2018 - 2030 (USD Million)
Table 16 Europe Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 17 Europe Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 18 Europe Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 19 Germany Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 20 Germany Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 21 Germany Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 22 UK Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 23 UK Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 24 UK Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 25 France Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 26 France Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 27 France Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 28 Italy Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 29 Italy Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 30 Italy Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 31 Spain Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 32 Spain Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 33 Spain Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 34 Denmark Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 35 Denmark Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 36 Denmark Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 37 Sweden Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 38 Sweden Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 39 Sweden Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 40 Norway Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 41 Norway Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 42 Norway Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 43 Asia Pacific Connective Tissue Disease market, by region, 2018 - 2030 (USD Million)
Table 44 Asia Pacific Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 45 Asia Pacific Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 46 Asia Pacific Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 47 China Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 48 China Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 49 China Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 50 Japan Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 51 Japan Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 52 Japan Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 53 India Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 54 India Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 55 India Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 56 South Korea Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 57 South Korea Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 58 South Korea Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 59 Australia Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 60 Australia Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 61 Australia Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 62 Thailand Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 63 Thailand Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 64 Thailand Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 65 Latin America Connective Tissue Disease market, by region, 2018 - 2030 (USD Million)
Table 66 Latin America Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 67 Latin America Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 68 Latin America Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 69 Brazil Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 70 Brazil Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 71 Brazil Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 72 Argentina Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 73 Argentina Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 74 Argentina Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 75 MEA Connective Tissue Disease market, by region, 2018 - 2030 (USD Million)
Table 76 MEA Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 77 MEA Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 78 MEA Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 79 South Africa Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 80 South Africa Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 81 South Africa Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 85 UAE Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 86 UAE Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 87 UAE Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
Table 88 Kuwait Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
Table 89 Kuwait Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
Table 90 Kuwait Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Connective Tissue Disease market: market outlook
Fig. 14 Connective Tissue Disease competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Connective Tissue Disease market driver impact
Fig. 18 Connective Tissue Disease market restraint impact
Fig. 19 Connective Tissue Disease market: Disease movement analysis
Fig. 20 Connective Tissue Disease market: Disease outlook and key takeaways
Fig. 21 Rheumatoid Arthritis (RA) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Systemic Lupus Erythematosus (SLE) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Scleroderma market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Polymyositis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Dermatomyositis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Sjogren's Syndrome market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Mixed Connective Tissue Disease (MCTD) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Undifferentiated Connective Tissue Disease (UCTD) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Other connective tissue diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Connective Tissue Disease market: Drug movement analysis
Fig. 31 Connective Tissue Disease market: Drug outlook and key takeaways
Fig. 32 Pharmaceuticals market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Disease-Modifying Anti-Rheumatic Drugs (DMARDs) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Corticosteroids market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Biopharmaceuticals market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Biologics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 TNF Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 IL-6 Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 B-cell Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 T-cell Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Other Biologics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Biosimilars market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Connective Tissue Disease market: Distribution channel movement analysis
Fig. 46 Connective Tissue Disease market: Distribution channel outlook and key takeaways
Fig. 47 Hospital Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Retail Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Online Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Global Connective Tissue Disease market: Regional movement analysis
Fig. 51 Global Connective Tissue Disease market: Regional outlook and key takeaways
Fig. 52 Global Connective Tissue Disease market share and leading players
Fig. 53 North America, by country
Fig. 54 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 U.S. key country dynamics
Fig. 56 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Canada key country dynamics
Fig. 58 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Mexico key country dynamics
Fig. 60 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 UK key country dynamics
Fig. 63 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Germany key country dynamics
Fig. 65 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 France key country dynamics
Fig. 67 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Italy key country dynamics
Fig. 69 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Spain key country dynamics
Fig. 71 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 Denmark key country dynamics
Fig. 73 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 74 Sweden key country dynamics
Fig. 75 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 76 Norway key country dynamics
Fig. 77 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 78 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 China key country dynamics
Fig. 80 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 Japan key country dynamics
Fig. 82 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 India key country dynamics
Fig. 84 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 85 Thailand key country dynamics
Fig. 86 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 87 South Korea key country dynamics
Fig. 88 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 89 Australia key country dynamics
Fig. 90 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 91 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 92 Brazil key country dynamics
Fig. 93 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 94 Argentina key country dynamics
Fig. 95 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 96 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 97 South Africa key country dynamics
Fig. 98 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 99 Saudi Arabia key country dynamics
Fig. 100 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 101 UAE key country dynamics
Fig. 102 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 103 Kuwait key country dynamics
Fig. 104 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 105 Market share of key market players - Connective Tissue Disease market